Compare OLMA & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLMA | MFA |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.9M | 957.0M |
| IPO Year | 2020 | N/A |
| Metric | OLMA | MFA |
|---|---|---|
| Price | $11.57 | $9.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $44.89 | $11.05 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.16% |
| EPS Growth | ★ 15.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.02 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.47 | $8.78 |
| 52 Week High | $36.26 | $10.57 |
| Indicator | OLMA | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 42.12 |
| Support Level | $7.79 | $8.90 |
| Resistance Level | $13.09 | $9.24 |
| Average True Range (ATR) | 0.64 | 0.16 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 26.37 | 22.22 |
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.